William E Dager1, Jeff H King. 1. Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, CA 95817-2201, USA. william.dager@ucdmc.ucdavis.edu
Abstract
BACKGROUND: Data are limited on aminoglycoside pharmacokinetic differences between acute renal failure (ARF) and chronic kidney disease (CKD) or infection survival when maintaining peak and pre-hemodialysis serum concentrations between 7 and 10 and 3.5 and 5 mg/L, respectively. OBJECTIVE: To report aminoglycoside pharmacokinetic observations in a consecutive series of patients receiving intermittent hemodialysis (IHD), including treatment impact of patient-specific dosing regimens. METHODS: In this prospective study, all calculated pharmacokinetic parameters used concentrations drawn more than 12 hours after the initial dose and peak concentrations at least 2 hours after the dose. Analysis included pharmacokinetic parameters in stage 5 CKD, ARF, impact of the dialysis prescription, and treatment results of individualized dosing regimens lasting more than 4 days. RESULTS: Consecutive patients with IHD (N = 167) receiving 216 courses of aminoglycosides were evaluated. The mean +/- SD volume of distribution was 0.39 +/- 0.15 L/kg ideal body weight, and elimination half-life during dialysis was 4.2 +/- 2.3 hours. The elimination half-life off IHD was 30% shorter in ARF (31.9 +/- 20.8 h) versus 45.7 +/- 24.2 hours in CKD (p < 0.001). Mean extrapolated peak concentrations and pre-IHD levels were 7.7 +/- 1.6 and 3.9 +/- 1.2 mg/L, respectively. A 91% treatment success rate was observed in 117 individualized treatment courses in 100 patients receiving greater than or equal to 5 days of aminoglycoside therapy. CONCLUSIONS: A large variability in aminoglycoside pharmacokinetic parameters in IHD exists, with aminoglycoside elimination off IHD significantly faster in ARF. Individualized regimens using serum concentrations drawn in patients requiring treatment (non-synergistic) targeting peak concentrations of 7-10 mg/L and pre-hemodialysis serum concentrations of 3.5-5 mg/L appears successful for eradicating infections.
BACKGROUND: Data are limited on aminoglycoside pharmacokinetic differences between acute renal failure (ARF) and chronic kidney disease (CKD) or infection survival when maintaining peak and pre-hemodialysis serum concentrations between 7 and 10 and 3.5 and 5 mg/L, respectively. OBJECTIVE: To report aminoglycoside pharmacokinetic observations in a consecutive series of patients receiving intermittent hemodialysis (IHD), including treatment impact of patient-specific dosing regimens. METHODS: In this prospective study, all calculated pharmacokinetic parameters used concentrations drawn more than 12 hours after the initial dose and peak concentrations at least 2 hours after the dose. Analysis included pharmacokinetic parameters in stage 5 CKD, ARF, impact of the dialysis prescription, and treatment results of individualized dosing regimens lasting more than 4 days. RESULTS: Consecutive patients with IHD (N = 167) receiving 216 courses of aminoglycosides were evaluated. The mean +/- SD volume of distribution was 0.39 +/- 0.15 L/kg ideal body weight, and elimination half-life during dialysis was 4.2 +/- 2.3 hours. The elimination half-life off IHD was 30% shorter in ARF (31.9 +/- 20.8 h) versus 45.7 +/- 24.2 hours in CKD (p < 0.001). Mean extrapolated peak concentrations and pre-IHD levels were 7.7 +/- 1.6 and 3.9 +/- 1.2 mg/L, respectively. A 91% treatment success rate was observed in 117 individualized treatment courses in 100 patients receiving greater than or equal to 5 days of aminoglycoside therapy. CONCLUSIONS: A large variability in aminoglycoside pharmacokinetic parameters in IHD exists, with aminoglycoside elimination off IHD significantly faster in ARF. Individualized regimens using serum concentrations drawn in patients requiring treatment (non-synergistic) targeting peak concentrations of 7-10 mg/L and pre-hemodialysis serum concentrations of 3.5-5 mg/L appears successful for eradicating infections.
Authors: Brian S Decker; Ahmed N Mohamed; Mary Chambers; Michael A Kraus; Sharon M Moe; Kevin M Sowinski Journal: Am J Nephrol Date: 2012-07-18 Impact factor: 3.754
Authors: Noha N Salama; Jonathan H Segal; Mariann D Churchwell; Jignesh H Patel; Lihong Gao; Michael Heung; Bruce A Mueller Journal: Nephrol Dial Transplant Date: 2009-12-10 Impact factor: 5.992
Authors: Kevin M Sowinski; Stephanie J Magner; Aroonrut Lucksiri; Meri K Scott; Richard J Hamburger; Bruce A Mueller Journal: Clin J Am Soc Nephrol Date: 2008-01-30 Impact factor: 8.237